159 related articles for article (PubMed ID: 37509156)
1. Molecular Evolutionary Landscape of the Immune Microenvironment of Head and Neck Cancer.
Shao B; Ye Z; Sun B; Xiao Z
Biomolecules; 2023 Jul; 13(7):. PubMed ID: 37509156
[TBL] [Abstract][Full Text] [Related]
2. Identification of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma (HNSC) for the Exploration of Immunotherapy and Prognosis.
Huang C; Liu J
Genet Res (Camb); 2022; 2022():6880760. PubMed ID: 36636556
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
[TBL] [Abstract][Full Text] [Related]
4. Identification of the Potential Correlation between Tumor Protein 73 and Head and Neck Squamous Cell Carcinoma.
Chen Y
Dis Markers; 2022; 2022():6410113. PubMed ID: 35756491
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of intra- and peritumoral immune cell subpopulations in head and neck squamous cell carcinomas - comprehensive analysis of the TCGA-HNSC cohort and immunohistochemical validation on 101 patients.
Knebel M; Körner S; Kühn JP; Wemmert S; Brust L; Smola S; Wagner M; Bohle RM; Morris LGT; Pandey A; Schick B; Linxweiler M
Front Immunol; 2023; 14():1172768. PubMed ID: 37383237
[TBL] [Abstract][Full Text] [Related]
6. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
[TBL] [Abstract][Full Text] [Related]
8. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
Huang J; Liang B; Wang T
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
[TBL] [Abstract][Full Text] [Related]
9. Profiles of immune cell infiltration in head and neck squamous carcinoma.
Liang B; Tao Y; Wang T
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32095823
[TBL] [Abstract][Full Text] [Related]
10. DNA-methylome-derived epigenetic fingerprint as an immunophenotype indicator of durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma.
Li R; Wen X; Lv RX; Ren XY; Cheng BL; Wang YK; Chen RZ; Hu W; Tang XR
Cell Oncol (Dordr); 2024 Feb; ():. PubMed ID: 38315286
[TBL] [Abstract][Full Text] [Related]
11. CCR5 as a prognostic biomarker correlated with immune infiltrates in head and neck squamous cell carcinoma by bioinformatic study.
Li C; Chen S; Liu C; Mo C; Gong W; Hu J; He M; Xie L; Hou X; Tang J; Ou M
Hereditas; 2022 Sep; 159(1):37. PubMed ID: 36167571
[TBL] [Abstract][Full Text] [Related]
12. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
Front Immunol; 2022; 13():975847. PubMed ID: 36091055
[TBL] [Abstract][Full Text] [Related]
13. Clinical powers of Aminoacyl tRNA Synthetase Complex Interacting Multifunctional Protein 1 (AIMP1) for head-neck squamous cell carcinoma.
Li Y; Liu H
Cancer Biomark; 2022; 34(3):359-374. PubMed ID: 35068446
[TBL] [Abstract][Full Text] [Related]
14. PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma.
Wang L; Chen K; Weng S; Xu H; Ren Y; Cheng Q; Luo P; Zhang J; Liu Z; Han X
World J Surg Oncol; 2023 Mar; 21(1):72. PubMed ID: 36864522
[TBL] [Abstract][Full Text] [Related]
15. Establishment of an immune-related gene prognostic model for head and neck tumors.
Zhou F; Chen AX; Lv HY; Liang DH; Yu HS
J Biol Regul Homeost Agents; 2021; 35(3):975-986. PubMed ID: 34159769
[TBL] [Abstract][Full Text] [Related]
16. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
17. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
[TBL] [Abstract][Full Text] [Related]
18. The characteristics and clinical relevance of tumor fusion burden in head and neck squamous cell carcinoma.
He L; Ren D; Lv G; Mao B; Wu L; Liu X; Gong L; Liu P
Cancer Med; 2023 Jan; 12(1):852-861. PubMed ID: 35621268
[TBL] [Abstract][Full Text] [Related]
19. A novel Pyroptosis-related long non-coding RNA signature for predicting the prognosis and immune landscape of head and neck squamous cell carcinoma.
Zhou C; Shen Y; Jin Y; Shen Z; Ye D; Shen Y; Deng H
Cancer Med; 2022 Dec; 11(24):5097-5112. PubMed ID: 35567376
[TBL] [Abstract][Full Text] [Related]
20. Subclass-Specific Prognosis and Treatment Efficacy Inference in Head and Neck Squamous Carcinoma.
Zheng Z; Xie W; Chen X; Wang F; Huang L; Li X; Lin Q; Wong KC
IEEE J Biomed Health Inform; 2022 Aug; 26(8):4303-4313. PubMed ID: 35439152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
